J&J Wants Comparative Effectiveness Studies on Long-Acting Anti-Psychotics
This article was originally published in The Pink Sheet Daily
Executive Summary
The Institute of Medicine's report on CE priorities, to be released June 30, may shape agenda across a number of product categories.
You may also be interested in...
J&J Takes Leaner, But Stronger Business Approach With Management Consolidation
The health care giant is eliminating some management positions with more organizational announcements expected in coming weeks.
J&J Takes Leaner, But Stronger Business Approach With Management Consolidation
The health care giant is eliminating some management positions with more organizational announcements expected in coming weeks.
J&J CNS Studies Show Awareness Of CER And Broader Databases
J&J's proposal to make long-acting anti-psychotic drugs a priority for the nation's push into comparative effectiveness research didn't make it onto the Institute of Medicine's "hot list" of research priorities released June 30 (1"The Pink Sheet" DAILY, June 30, 2009)